Dose-response effects of inactivated Newcastle disease vaccines: influence of serologic assay, time after vaccination, and type of chickens.
Knowledge of the dose-response relation of inactivated vaccines and of the factors that influence this relation is essential for the evaluation of existing vaccine potency assays and the development of new potency assays that are based on the antigen content of the inactivated vaccines. We quantified the relation between vaccine dose, serologic response, and clinical protection after vaccination for three different inactivated Newcastle disease (ND) vaccines. Qualitatively, similar dose-response curves were obtained for the three vaccines when either the serologic response or the clinical protection of specific-pathogen-free (SPF) chickens was plotted against the different vaccine doses applied. However, the vaccines differed quantitatively: doses of vaccines that induced similar antibody titers or clinical protection differed 2-8-fold. In contrast with the narrow range of antibody titers induced by a full vaccine dose, a very broad range of titers was obtained after dilution of the vaccines. At least 95% of the SPF chickens with detectable antibody in the serum were protected against a challenge with virulent Herts ND virus. The relation between the dosage of two different ND vaccines and the serum antibody titers remained markedly constant between 3 and 18 wk after vaccination. Vaccination of broilers instead of layers with a dilution series of inactivated ND vaccine resulted in significantly lower antibody levels and less clinical protection against virulent challenge. In conclusion, despite quantitative differences, we found comparable dose-response relations for the three inactivated ND vaccines studied.
Maas
R A
RA
Oei
H L
HL
Venema-Kemper
S
S
Koch
G
G
Bongers
J
J
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D002478:Cells, Cultured; D002642:Chick Embryo; D002645:Chickens; D004305:Dose-Response Relationship, Drug; D006385:Hemagglutination Inhibition Tests; D009500:Neutralization Tests; D009521:Newcastle Disease / Q000276:immunology* / Q000517:prevention & control; D009522:Newcastle disease virus / Q000302:isolation & purification; D013045:Species Specificity; D013047:Specific Pathogen-Free Organisms; D014613:Vaccines, Attenuated / Q000494:pharmacology / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000494:pharmacology / Q000627:therapeutic use*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines